Objective To investigate the clinical efficacy and safety of botulinum neurotoxin type A(BTX-A)local injection in the treatment of Raynaud's phenomenon(RP)associated with connective tissue disease.Methods Subjects with no difference in baseline data of both hands were included.Subjects were randomly selected to inject BTX-A in the area of bifurcation of neurovascular bundle around fingers with one hand as the injection side and the other hand as the control side.Visual analogue pain scale(VAS)scores,Raynaud's score(RS)and ulcer score(RS)were recorded at 0,2,8 and 12 weeks score,US),average fingertip skin temperature,average capillary filling time and occurrence of adverse reactions were statistically analyzed by SPSS 25.0 software.Results 27 patients completed treatment and follow-up.After 2,8,and 12 weeks of treatment,there was a sta-tistical difference in the overall mean VAS score between the injection side and the control side.After 8,12 weeks of treatment,there was a statistically significant difference in the mean Reynolds score between the injection side and the control side.There were no significant differences in Reynolds score at 2 weeks,ulcer score at 2,8 and 12 weeks,average fingerend skin tempera-ture and average percutaneous oxygen saturation.VAS scores at 2,8 and 12 weeks of treatment were statistically significant compared with those before treatment,Raynaud scores at 8 and 12 weeks of treatment were statistically significant compared with those before treatment,ulcer scores at 8 and 12 weeks of treatment were statistically significant compared with those before treatment,there was no significant difference in the remaining observation indicators before and after treatment.Conclusion Local injection of botulinum toxin type A can improve the pain of patients with Raynaud,reduce the frequency of Raynaud phe-nomenon,promote ulcer healing with less adverse reactions,and is a safe,effective,simple and feasible method.
NETL
NSTL
万方数据
